Sugi Predict
/ Targets
/ DCK
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to DCK by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Acelarin First Line Randomised Pancreatic Study |
PHASE2/PHASE3 | SUSPENDED |
| Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
PHASE3 | COMPLETED |
| Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome |
PHASE2 | COMPLETED |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
PHASE2 | COMPLETED |
| Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV |
PHASE1/PHASE2 | COMPLETED |
| D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC) |
PHASE1/PHASE2 | UNKNOWN |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer |
PHASE2 | COMPLETED |
| Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
PHASE2 | COMPLETED |
| PKC412 and 5-Azacytidine |
PHASE1/PHASE2 | COMPLETED |
| Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer |
PHASE2 | COMPLETED |
| PRO#0118: Decitabine Plus Mini Flu-Bu |
PHASE1 | COMPLETED |
| Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors |
PHASE1 | RECRUITING |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma |
PHASE1 | UNKNOWN |
| 5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer |
PHASE1 | COMPLETED |
| Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia |
PHASE1 | WITHDRAWN |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations |
PHASE1 | COMPLETED |
| Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer |
PHASE1 | COMPLETED |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies |
PHASE1 | COMPLETED |
| A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors |
EARLY_PHASE1 | UNKNOWN |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx |
EARLY_PHASE1 | COMPLETED |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) |
nan | UNKNOWN |
| Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor |
nan | UNKNOWN |
| Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma |
nan | COMPLETED |
| Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia |
nan | UNKNOWN |
| Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a DCK binder may also engage these)